Minimal residual disease detected by immunoglobulin sequencing predicts CLL relapse more effectively than flow cytometry

被引：4

作者：

Aw, Andrew ^{[1
]}

Kim, Haesook T. ^{[2
]}

Fernandes, Stacey M. ^{[3
]}

Hoang, Kevin ^{[3
]}

Kasar, Siddha ^{[3
]}

Faham, Malek ^{[4
]}

Brown, Jennifer R. ^{[5
,6
]}

机构：

[1] Univ Ottawa, Ottawa Hosp, Div Hematol, Dept Med, Ottawa, ON, Canada

[2] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA

[3] Dana Farber Canc Inst, Boston, MA 02115 USA

[4] Adapt Biotechnol Corp, San Francisco, CA USA

[5] Harvard Med Sch, CLL Ctr, Dana Farber Canc Inst, Boston, MA USA

[6] Harvard Med Sch, Dept Med Oncol, Dana Farber Canc Inst, Boston, MA USA

来源：

LEUKEMIA & LYMPHOMA | 2018年 / 59卷 / 08期

关键词：

CHRONIC LYMPHOCYTIC-LEUKEMIA; INDEPENDENT PREDICTOR; QUANTIFICATION; SURVIVAL; ERADICATION; THERAPY; PRIMERS;

D O I：

10.1080/10428194.2017.1397664

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1986 / 1989

页数：4

共 15 条

[1] Minimal Residual Disease Quantification Is an Independent Predictor of Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia: A Multivariate Analysis From the Randomized GCLLSG CLL8 Trial [J].

Boettcher, Sebastian ;

Ritgen, Matthias ;

Fischer, Kirsten ;

Stilgenbauer, Stephan ;

Busch, Raymonde M. ;

Fingerle-Rowson, Guenter ;

Fink, Anna Maria ;

Buehler, Andreas ;

Zenz, Thorsten ;

Wenger, Michael Karl ;

Mendila, Myriam ;

Wendtner, Clemens-Martin ;

Eichhorst, Barbara F. ;

Doehner, Hartmut ;

Hallek, Michael J. ;

Kneba, Michael .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (09) :980-988

[2] Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia [J].

Faham, Malek ;

Zheng, Jianbiao ;

Moorhead, Martin ;

Carlton, Victoria E. H. ;

Stow, Patricia ;

Coustan-Smith, Elaine ;

Pui, Ching-Hon ;

Campana, Dario .

BLOOD, 2012, 120 (26) :5173-5180

[3]

Herrera A.F., 2015, BLOOD, V126, P3156

[4] Minimal residual disease is an independent predictor for 10-year survival in CLL [J].

Kwok, Marwan ;

Rawstron, Andy C. ;

Varghese, Abraham ;

Evans, Paul A. S. ;

O'Connor, Sheila J. M. ;

Doughty, Chi ;

Newton, Darren J. ;

Moreton, Paul ;

Hillmen, Peter .

BLOOD, 2016, 128 (24) :2770-2773

[5] Minimal residual disease quantification using consensus primers and high- throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia [J].

Logan, A. C. ;

Zhang, B. ;

Narasimhan, B. ;

Carlton, V. ;

Zheng, J. ;

Moorhead, M. ;

Krampf, M. R. ;

Jones, C. D. ;

Waqar, A. N. ;

Faham, M. ;

Zehnder, J. L. ;

Miklos, D. B. .

LEUKEMIA, 2013, 27 (08) :1659-1665

[6] High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment [J].

Logan, Aaron C. ;

Gao, Hong ;

Wang, Chunlin ;

Sahaf, Bita ;

Jones, Carol D. ;

Marshall, Eleanor L. ;

Buno, Ismael ;

Armstrong, Randall ;

Fire, Andrew Z. ;

Weinberg, Kenneth I. ;

Mindrinos, Michael ;

Zehnder, James L. ;

Boyd, Scott D. ;

Xiao, Wenzhong ;

Davis, Ronald W. ;

Miklos, David B. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (52) :21194-21199

[7] Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia [J].

Moreno, Carol ;

Villamor, Neus ;

Colomer, Dolors ;

Esteve, Jordi ;

Giné, Eva ;

Muntañola, Ana ;

Campo, Elias ;

Bosch, Francesc ;

Montserrat, Emili .

BLOOD, 2006, 107 (11) :4563-4569

[8] Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival [J].

Moreton, P ;

Kennedy, B ;

Lucas, G ;

Leach, M ;

Rassam, SMB ;

Haynes, A ;

Tighe, L ;

Oscier, D ;

Fegan, C ;

Rawstron, A ;

Hillmen, P .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (13) :2971-2979

[9] A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study [J].

Rawstron, A. C. ;

Fazi, C. ;

Agathangelidis, A. ;

Villamor, N. ;

Letestu, R. ;

Nomdedeu, J. ;

Palacio, C. ;

Stehlikova, O. ;

Kreuzer, K-A ;

Liptrot, S. ;

O'Brien, D. ;

de Tute, R. M. ;

Marinov, I. ;

Hauwel, M. ;

Spacek, M. ;

Dobber, J. ;

Kater, A. P. ;

Gambell, P. ;

Soosapilla, A. ;

Lozanski, G. ;

Brachtl, G. ;

Lin, K. ;

Boysen, J. ;

Hanson, C. ;

Jorgensen, J. L. ;

Stetler-Stevenson, M. ;

Yuan, C. ;

Broome, H. E. ;

Rassenti, L. ;

Craig, F. ;

Delgado, J. ;

Moreno, C. ;

Bosch, F. ;

Egle, A. ;

Doubek, M. ;

Pospisilova, S. ;

Mulligan, S. ;

Westerman, D. ;

Sanders, C. M. ;

Emerson, R. ;

Robins, H. S. ;

Kirsch, I. ;

Shanafelt, T. ;

Pettitt, A. ;

Kipps, T. J. ;

Wierda, W. G. ;

Cymbalista, F. ;

Hallek, M. ;

Hillmen, P. ;

Montserrat, E. .

LEUKEMIA, 2016, 30 (04) :929-936

[10] Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL [J].

Rawstron, A. C. ;

Boettcher, S. ;

Letestu, R. ;

Villamor, N. ;

Fazi, C. ;

Kartsios, H. ;

de Tute, R. M. ;

Shingles, J. ;

Ritgen, M. ;

Moreno, C. ;

Lin, K. ;

Pettitt, A. R. ;

Kneba, M. ;

Montserrat, E. ;

Cymbalista, F. ;

Hallek, M. ;

Hillmen, P. ;

Ghia, P. .

LEUKEMIA, 2013, 27 (01) :142-149

← 1 2 →